Ozanimod
| Status | Pipeline |
| Development phase | Initial stage |
| Therapeutic cat. | Other |
| Polymorphic form | |
| CAS No. | 1306760-87-1 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | 4 |
| Samples | 2025 |
Drug description
Ozanimod is used to treat relapsing forms of multiple sclerosis in adults (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease). Ozanimod is used only if you have a specific genotype. Ozanimod is also used to treat adults with moderately to severely active ulcerative colitis. It is not known if this medicine is safe and effective in children.
Polpharma API
- Samples availability: 2025
- OEB 4
- Initial stage
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
